
Replacing two cycles of intensive chemotherapy with Blincyto raised four-year event-free survival to 83% from 70.3% in children with high-risk B-cell ALL, with far fewer infections.
For Childhood Cancer Awareness Month, here’s a round-up of the latest news and updates in this disease space.
For Childhood Cancer Awareness Month, here’s a round-up of the latest news and updates in this disease space:






